TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Risk of Shopping Behavior of Tapentadol Immediate-Release (IR) Compared to Oxycodone Immediate-Release (IR)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Opioid naive patients (a patient who has not received an opioid of any type in the 3 months before the index date) exposed to tapentadol IR or oxycodone IR from July 2009 to December 2010 \[The index date is the date of the first prescription for tapentadol IR or oxycodone IR after June 30, 2009\]~Exclusion Criteria:~* Patients with use of any opioid 3 months before the index date~* Patients who within 4 days on or after the index date fill a prescription for a different opioid~* Patients who within 4 days on or after the index date fill a prescription for the same opioid but written by a different prescriber

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tapentadol IR (Type: None): None
- Oxycodone IR (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Previously diagnosed (e.g. more than 6 months ago) primary or secondary adrenal insufficiency with a stable daily glucocorticoid substitution dose for at least 3 months prior to study entry~* Signed informed consent to participate in the study~Exclusion Criteria:~* acute primary or secondary adrenal insufficiency~* clinical or laboratory signs of significant cerebral, cardiovascular, respiratory, hepatobiliary, pancreatic disease~* clinically significant renal dysfunction~* any medication with agents which could interfere with glucocorticoid kinetics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Plenadren (Type: EXPERIMENTAL): Plenadren (modified release hydrocortison) 20-25 or 30 mg oral tablets will be administered once-daily at 8.00 AM in the fasting state The dose is kept the same as patients had before entering the trial.
- Conventional glucocorticoid therapy (Type: ACTIVE_COMPARATOR): Hydrocortisone (dose range 10 to 30) mg will be continued as before entering the study. Cortisone Acetate (dose 25 to 37.5 mg) will be continued as before entering the study. The morning dose will be administered in the fasting state.~The total daily dose and timing is not changed during the study period.
- Healthy volunteers (Type: NO_INTERVENTION): Healthy volunteers will be enrolled as control group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating JUVÉDERM® VOLUMA® XC Injectable Gel for Correction of Temple Hollowing in Adult Participants ≥ 22 Years Old

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants in general good health~* Participants seeking improvement of temple hollowing~Exclusion Criteria:~* Temple hollowing due to trauma, congenital malformations, or lipodystrophy~* Temporomandibular joint dysfunction or any other jaw issues~* Recurrent temporal headaches such as temporal tendinitis migraine~* Active autoimmune disease~* History of anaphylaxis or allergy to lidocaine (or any amide-based anesthetics), HA products, or Streptococcal protein~* Prior facial reconstructive surgeries, facelift, or browlift as well as surgeries on the temple area (eg, biopsy)~* Fat injection or permanent facial implants anywhere in the face~* Semipermanent soft-tissue filler treatment in the temple or mid-face within 36 months before enrollment~* Temporary dermal filler injections above the subnasale within 24 months before enrollment~* Mesotherapy or cosmetic facial procedures above the subnasale within 6 months before enrollment~* Botulinum toxin treatment above the subnasale within 6 months before enrollment~* Females who are pregnant, nursing, or planning a pregnancy

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- No Treatment then JUVÉDERM® VOLUMA® XC (Type: OTHER): Participants received no treatment for 3 months during the Control Period. They either exited the study at Month 3 or received an optional treatment with JUVÉDERM® VOLUMA® XC injectable gel treatment in both temples during the Post-Control Period and an optional touch-up treatment 30 days later. Participants did not receive any treatment during the Maintenance Treatment Period.
- JUVÉDERM® VOLUMA® XC (Type: EXPERIMENTAL): Participants received JUVÉDERM® VOLUMA® XC injectable gel treatment in both temples during the Control Period followed by an optional touch-up treatment 30 days later. Participants exited the study at Month 13 or received an optional maintenance treatment and were followed for 6 months during the Maintenance Treatment Period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pediatric Postoperative Analgesia With Quadratus Lumborum Block(QLB) And Dexamethasone As An Adjuvant To Bupivacaine.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Pediatric patients(6-12 years)~* ASA physical status I,II~* Abdominal surgery~Exclusion Criteria:~* Parents refusal or legal guardian's refusal~* Allergy to bupivacaine or dexamethasone~* Contraindications to regional techniques~* Failed QLB~* Infection on site of procedure

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: t

Study Arms:
- Group A Quadratus Lumborum Block with dexamethasone IV (Type: ACTIVE_COMPARATOR): QLB with (0.5 mL/kg of bupivacaine 0.25%) and IV dexamethasone (0.1-0.3 mg/kg with a maximum dose 10 mg) added to 5 mL normal saline
- Group B Quadratus Lumborum Block with dexamethasone locally (Type: ACTIVE_COMPARATOR): QLB with (0.5 mL/kg of bupivacaine 0.25% plus dexamethasone 0.1 mg/kg), and IV 5 mL normal saline
- Group C Quadratus Lumborum Block with bupivacaine alone (Type: PLACEBO_COMPARATOR): Patients will receive QLB (0.5 mL/kg of bupivacaine 0.25%) and IV 5 mL normal saline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with Type 2 diabetes mellitus~* Treated with metformin within a defined dose range for at least 3 months prior to screening~* BMI= 27-45 kg/m2~* HbA1c value between 7.5% and 11%~Exclusion Criteria:~* Treated with oral anti-diabetic medications other than metformin within 3 months of screening~* Patients treated previously with AC2993~* Patients presently treated with insulin

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- AC2993 5 mcg (0.02 mL) (Type: EXPERIMENTAL): Placebo, then AC2993 5 mcg, then AC2993 5 mcg
- AC2993 10mcg (0.04 mL) (Type: EXPERIMENTAL): Placebo, then AC2993 5 mcg, then AC2993 10 mcg
- Placebo 0.02 mL (Type: PLACEBO_COMPARATOR): Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.02 mL
- Placebo 0.04 mL (Type: PLACEBO_COMPARATOR): Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.04 mL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Domperidone on the Nutrient Composition of Preterm Mother's Breast Milk

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* i. Mother of an infant born less than 31 weeks gestation~* ii. Women mechanically expressing breast milk using a double collecting system~* iii. Experiencing lactation failure indicated by at least one of the following: A decreasing milk supply (by greater than 30 percent from peak volume based on maternal account) An inability to provide adequate breast milk to meet the daily nutritional intake of their infant~* iv. Women who have had little or no improvement in milk production following education/counseling with a lactation consultant/Neonatal Intensive Care nurse with respect to non-pharmacological techniques.~* v. Postpartum period equal to or greater than three weeks.~Exclusion Criteria:~* i. Participants receiving any medication known to alter the effect of domperidone (e.g.cimetidine, ranitidine, famotidine, and nizatidine) or medication that interacts with domperidone (e.g. haloperidol, lithium).~* ii. Experiencing mastitis~* iii. Having a chronic or debilitating illness.~* iv. Previous breast surgery~* v. Having a known lactose intolerance

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Domperidone (Type: EXPERIMENTAL): Domperidone
- placeob- Sugar pill (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Metastatic Castration-Resistant Prostate Cancer Progression after one or two prior cytotoxic chemotherapies~* At least one chemotherapy must have contained docetaxel~* Eastern Cooperative Oncology Group (ECOG) Performance Status \<= 2~* Medical or surgical castration with testosterone \< 50 ng/dL~* Adequate bone marrow, hepatic and renal function~* Potassium \>= 3.5 mmol/L~* Able to swallow the study drug whole as a tablet~* Informed Consent~Exclusion Criteria:~* More than two prior cytotoxic chemotherapy regimens~* Prior Ketoconazole for prostate cancer~* Prior abiraterone acetate or other CYP17 inhibitor or investigational agents targeting the androgen receptor for prostate cancer~* Uncontrolled hypertension~* Active or symptomatic viral hepatitis or chronic liver disease~* History of pituitary or adrenal dysfunction~* Clinically significant heart disease~* Other malignancy~* Known brain metastasis~* GI disorder affecting absorption~* Not willing to use contraception

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abiraterone acetate plus prednisone/prednisolone (Type: EXPERIMENTAL): None
- Placebo plus prednisone/prednisolone (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, of any race, at least 18 years of age (inclusive).~* Freely provides both verbal and written informed consent.~* Has an area of plaque psoriasis appropriate for topical treatment that covers a body surface area (BSA) of at least 3%, but no more than 12%. The face, scalp, palms, soles, axillae, and intertriginous areas are to be excluded in this calculation.~* Is willing and able to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural and artificial) for the duration of the study.~* Has a clinical diagnosis of psoriasis at the Baseline visit with an IGA score of 3 or 4. (The face, scalp, palms, soles, axillae and intertriginous areas are to be excluded in this assessment).~Exclusion Criteria:~* Has spontaneously improving or rapidly deteriorating plaque psoriasis or pustular psoriasis, as determined by the Investigator.~* Presents with psoriasis that was treated with prescription medication and failed to respond to treatment, even partially or temporarily, as determined by the Investigator.~* Presents with any concurrent skin condition that could interfere with the evaluation of the treatment areas, as determined by the Investigator.~* Is pregnant, nursing an infant, or planning a pregnancy during the study period.~* Has received treatment with any investigational drug or device within 60 days or 5 drug half-lives (whichever is longer) prior to the Baseline visit or is concurrently participating in another clinical study with an investigational drug or device.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDP-122 Lotion (Type: EXPERIMENTAL): Participants will apply IDP-122 Lotion (halobetasol propionate \[HP\] 0.01%) topically once daily for 8 weeks.
- IDP-122 Vehicle Lotion (Type: PLACEBO_COMPARATOR): Participants will apply IDP-122 Vehicle Lotion topically once daily for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin Deficiency in Immigrants, a Treatment Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Serum- vitamin D below 75 nmol/L~* Men and female~* 25-65 years of age~* Born in Middle East or Africa, living in Umeå district~Exclusion Criteria:~* Hypersensitive to Cholecalciferol, cocos oil, palm kernel or rubber~* Serum D3 equal to or above75 nmol/L~* Hypercalcemia~* Renal insufficiency~* History of Kidney Calculi~* Nephrocalcinosis~* History of sarcoidosis and other Granulomatous Diseases~* Known malignancy~* Ongoing treatment with phenytoin, barbiturates, rifampicin, isoniazid~* Ongoing treatment with cardiac glycosides~* Ongoing treatment with thiazides~* Ongoing treatment with Etalpha, Rocaltrol, ergocalciferol, Dygratal~* Ongoing treatment with drugs involving fat absorption; Orlistat Colestyramin~* Oral treatment with glucocorticoids~* Ongoing treatment with Aluminum Compounds drugs~* Ongoing treatment with Omega -3, vitamin D and/or calcium~* Immobilisation~* Other medial reason not to participate according to the investigator~* Pregnancy (women with S-D3 below 25 nmol/)~* Breastfeeding

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Vitamin D3, 10 000 IU daily. Treatment to patients with Serum-vitamin D levels below 25 nmol/L
- Group 2a (Type: EXPERIMENTAL): Vitamin D3 2000 IU daily, one of two arms that patients with Serum-vitamin D levels between 25 nmol/L and 49 nmol/l will be randomised to
- Group 2b (Type: EXPERIMENTAL): Vitamin D3 2000 IU weekly, one of two arms that patients with Serum-vitamin D levels between 25 nmol/L and 49 mol/l will be randomised to
- Group 3 (Type: EXPERIMENTAL): Vitamin D3, 2000 IU daily i.e. 3 drops orally once daily for 12 weeks, treatment to patients with Serum-vitamin D levels between 50 and 74 nmol/L

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence of Rebamipide in Korean

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects were selected after passing a clinical screening procedure that included a physical examination and laboratory tests (blood analysis; hemoglobin, hematocrit, RBC, WBC, platelet, differential counting of WBC, total proteins, albumin, ALT, AST, alkaline phosphatase, total bilirubin, cholesterol, creatinine, blood urea nitrogen, and fasting glucose and urine analysis; specific gravity, color, pH, sugar, albumin, bilirubin, RBC, WBC and cast).~Exclusion Criteria:~* Subjects possibly sensitive to this type of preparation,~* Subjects who had a history of any hepatic illness,~* Subjects who had a history of any renal illness,~* Subjects who had a history of any respiratory illness,~* Subjects who had a history of any endocrine illness,~* Subjects who had a history of any cardiovascular system illness,~* Subjects who had taken alcohol within 4 weeks prior to the study,~* Subjects who had taken other preparations within 4 weeks prior to the study.

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Rebamipide, Serum concentration, Tablet (Type: EXPERIMENTAL): The test preparation, Rebamide® (containing 100 mg of rebamipide; lot No. KP005; expiration date, April 2010; Kyungdong Pharmaceutical Company, Seoul, Korea) and the reference preparation, Mucosta® (containing 100 mg of rebamipide; lot No. MC704067; expiration date, May 2010; Korea Otsuka Pharmaceuticals Co., Ltd., Seoul, Korea)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Cotrimoxazole in HIV- and HAART-exposed Infants

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Both maternal and infant criteria need to be met:~Maternal Inclusion Criteria:~* documented HIV infection~* taking 3-drug highly active antiretroviral therapy at any point during pregnancy (note: can include 2 NRTI+NNRTI, 2NRTI+PI, or 3 NRTI)~* 21 years of age or older, and able and willing to sign informed consent~* Proof of Botswana Citizenship~Maternal Exclusion Criteria:~* involuntary incarceration~Infant Inclusion Criteria:~* younger than 42 days of age~* able to be brought to regular visits at study clinic until at least 6 months postpartum~Infant Exclusion Criteria:~* known pre-existing birth anomalies resulting in a high probability that the baby will not survive to 6 months~* known hypersensitivity to cotrimoxazole

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cotrimoxazole (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Premenopausal, hormone receptor-positive patient~* Histologically verified (minimally) invasive breast cancer, local radical treatment~* 0-9 involved axillary lymph nodes (≥ 10 histologically examined nodes)~* Tumor stage: pT1b-3, yT0 or yT1a~Exclusion Criteria:~* T1a, T4d, yT4; M1~* Previous breast tumor irradiation~* Previous or concurrent chemotherapy (except for preoperative chemotherapy)~* Serum creatinine \> 1.5 x UNL or creatinine clearance \< 60 ml/min

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: 59 Years
- Healthy Volunteers: f

Study Arms:
- AZ (Arimidex+Zoledronate) (Type: ACTIVE_COMPARATOR): Study Drugs Arimidex (Anastrozole), Zometa (Zoledronate; zoledronic acid)
- TZ (Tamoxifen+Zoledronate) (Type: ACTIVE_COMPARATOR): Study Drugs Nolvadex (Tamoxifen), Zometa (Zoledronate; zoledronic acid)
- AC (Arimidex Control) (Type: ACTIVE_COMPARATOR): Study Drug Arimidex (Anastrozole)
- TC (Tamoxifen Control) (Type: ACTIVE_COMPARATOR): Study Drug Nolvadex (Tamoxifen)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenocity and Safety of Flubio (Influenza HA) Vaccine in Infants and Children (Bridging Study)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy~* Parents have been informed properly regarding the study and signed the informed consent form~* Parents will commit themselves to comply with the instructions of the investigator and the schedule of the trial~Exclusion Criteria:~* Subjects concomitantly enrolled or scheduled to be enrolled in another trial~* Evolving mild, moderate, or severe illness, especially infectious diseases or fever (axillary temperature \>=37oC)~* Known history of allergy to egg and/or chicken protein or any other component of the vaccines~* Known history of uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection~* Subject who has received a treatment likely to alter the immune response in the previous 4 weeks (intravenous immunoglobulins, blood-derived products or long term corticotherapy (\>2 weeks)).~* Any abnormality or chronic disease justified by investigator that might interfere assessment of the trial objectives.~* Subjects has been immunized with influenza vaccine within 1 year~* Subjects receives any vaccination within 1 months before and after immunization of Flubio.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 11 Years
- Healthy Volunteers: t

Study Arms:
- Vaccine (Type: EXPERIMENTAL): Vaccine~Flubio (Influenza HA) vaccine~2 doses for infants and children (6 months - 8 years old)~1 doses for children (9-11 years old)~The vaccine will be given intramuscularly

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete